Discover
NUVB
Nuvation Bio Inc.
5.00
5600 x 4.86
3700 x 5.10
bid
ask
+
0.05
1.01%
4650 @ 05:09 PM
5.00 +0.00 (0.00%)
| Ytd | -44.20% | |
| 1y | 33.33% |
4.87
day range
5.06
3.41
52 week range
9.54
| Open | 4.95 | Prev Close | 4.95 | Low | 4.87 | High | 5.06 | Mkt Cap | 1.76B |
| Vol | 2.96M | Avg Vol | 5.65M | EPS | -0.44 | P/E | N/A | Forward P/E | -333.33 |
| Beta | 1.62 | Short Ratio | 11.17 | Inst. Own | 67.60% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-02 | 50-d Avg | 6.21 | 200-d Avg | 5.70 | 1yr Est | 13.00 |
NUVB News
benzinga.com
This Ciena Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage: Buy on FORM ($200), NUVB ($12); Outperform on CIEN ($440); Neutral on E
benzinga.com
Citigroup Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $12
Citigroup analyst Geoff Meacham initiates coverage on Nuvation Bio (NYSE:NUVB) with a Buy rating
benzinga.com
Why Is Nuvation Bio Stock Gaining Thursday?
Nuvation Bio (NUVB) stock jumps 6% after early FDA label update for IBTROZI, highlighting over 4 yea
benzinga.com
Nuvation Bio Says FDA Approves sNDA For IBTROZI, ROS1 Inhibitor For Treatment Of Locally Advanced Or
Updated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 monthsNo changes t
benzinga.com
Citizens Reiterates Market Outperform on Nuvation Bio, Maintains $10 Price Target
Citizens analyst Silvan Turkcan reiterates Nuvation Bio (NYSE:NUVB) with a Market Outperform and
benzinga.com
Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target
Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and main
benzinga.com
Nuvation Bio Announces New Subgroup Analyses From Pivotal TRUST-I And TRUST-II Studies Evaluating IB
Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, includi